Pemazyre Alternatives Compared
| Pemazyre (pemigatinib) | Lytgobi (futibatinib) | Pemigatinib |
|
|---|
| Pemazyre (pemigatinib) | Lytgobi (futibatinib) | Pemigatinib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cholangiocarcinoma, Myeloid/Lymphoid Neoplasms. Pemazyre may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cholangiocarcinoma. Lytgobi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cholangiocarcinoma, Myeloid/Lymphoid Neoplasms. Pemigatinib may also be used for purposes not listed in this medication guide. |
Related suggestions Cholangiocarcinoma
|
|||||||||||||||
| More about Pemazyre (pemigatinib) | More about Lytgobi (futibatinib) | More about Pemigatinib | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Pemazyre has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Be the first to share your experience with this drug. |
Pemigatinib has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Pemazyre side effects |
View all Lytgobi side effects |
View all Pemigatinib side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Pemazyre prices |
View all Lytgobi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
N/A |
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
N/A |
Pemazyre | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
15.4 hours |
2.9 hours |
15.4 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 296 drugs are known to interact with Pemazyre:
|
A total of 179 drugs are known to interact with Lytgobi:
|
A total of 296 drugs are known to interact with Pemigatinib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
April 17, 2020 |
N/A |
April 17, 2020 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.